Efficacy of radiotherapy combined with atezolizumab or docetaxel in patients with previously treated NSCLC
Summary: Radiotherapy showed synergy with immunotherapy, yet the comparative effectiveness of combining immunotherapy (iRT) or chemotherapy (CRT) after platinum therapy failure in advanced non-small cell lung cancer (NSCLC) remains unexplored. We analyzed 163 patients (iRT: n = 120 vs. CRT: n = 43)...
Saved in:
| Main Authors: | Junzhu Xu, Haitao Wang, Chi Zhang, Su-Han Jin, Xiaofei Chen, Fangya Tan, Benjamin Frey, Markus Hecht, Jian-Guo Sun, Udo S. Gaipl, Hu Ma, Jian-Guo Zhou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004224025884 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Quality-of-life scale machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer
by: Juanyan Shen, et al.
Published: (2025-07-01) -
Feasibility and Safety of Anlotinib Plus Docetaxel versus Docetaxel Monotherapy in Patients with Previously Immunotherapy-Treated NSCLC: A Retrospective Exploratory Study
by: Li DW, et al.
Published: (2025-04-01) -
Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis
by: Helal F. Hetta, et al.
Published: (2025-04-01) -
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study
by: Enriqueta Felip, et al.
Published: (2025-08-01) -
Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC
by: Julia Meidenbauer, et al.
Published: (2024-10-01)